News, Resources, Updates
A scientific hub to keep you informed about our latest research and company updates.
Phenotyping of a C3-PMP22 mouse model of CMT1A
Charcot-Marie Tooth (CMT) disease is a hereditary, demyelinating peripheral neuropathy, leading to progressive muscle atrophy, weakness and subsequent walking disabilities and sensory impairments. Charcot-Marie Tooth Type 1A (CMT1A) is the most common type of CMT,...
Glomerular filtration rate (GFR) in the ADPKD mouse model
Preclinical studies aiming to assess kidney function traditionally include readouts such as serum creatinine and/or blood urea nitrogen (BUN). However, the use of readouts that are more clinically relevant such as glomerular filtration rate (GFR) is highly encouraged,...
Characterization of a transgenic TDP-43 Mouse Model
Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease characterized by progressive loss of upper and lower motoneurons. This leads to brain degeneration and muscle denervation, resulting in extensive muscle atrophy and functional motor impairments....
Effect of Salsalate on disease progression in the ADPKD Mouse Model
Salsalate is a pro-drug dimer of salicylate belonging to the family of NSAIDs, activating AMPK through direct interactions with the drug-binding domain of the AMPK beta-1 isoform. As such, Salsalate arises as a key candidate for drug repurposing in ADPKD. To...
Tumor microenvironment (TME) multiplex immunophenotyping analyses
The use of preclinical orthotopic tumors to better recapitulate the tumor microenvironment (TME) Complex interactions between the cellular and structural components of the tumor microenvironment (TME) composed of tumor cells, fibroblasts, endothelial cells, immune...
Characterization of a Spinal Cord Injury (SCI) Mouse Model
Spinal cord injury (SCI) is a condition mainly resulting from traumatic injuries caused by falls, or (road traffic) accidents. Currently, many novel therapeutics ranging from small molecules, (stem) cell transplants to medical devices are evaluated for their efficacy...
info@innoserlaboratories.com